Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - PDS Biotechnology Corpex32_2.htm
EX-31.2 - EXHIBIT 31.2 - PDS Biotechnology Corpex31_2.htm
EX-31.1 - EXHIBIT 31.1 - PDS Biotechnology Corpex31_1.htm
10-Q - 10-Q - PDS Biotechnology Corpform10q.htm

Exhibit 32.1

CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of Edge Therapeutics, Inc. (the “Company”), on Form 10-Q for the quarter ended June 30, 2018 (the “Report”), I, Brian A. Leuthner, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:

(1)
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 1, 2018
/s/ Brian A. Leuthner
 
Brian A. Leuthner
 
President and Chief Executive Officer
 
(Principal Executive Officer)